| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*See the Appendix on page 1439 for a complete list of members of the FSH-DY Group.
From the Department of Neurology (Drs. Kissel and Mendell, and W. King), The Ohio State University, Columbus; and the Department of Neurology and the Wayne C. Gorrell Jr. Molecular Biology Laboratory (Drs. Tawil, McDermott, and Griggs, and S. Pandya) and the Department of Biostatistics (Dr. McDermott), University of Rochester School of Medicine and Dentistry, Rochester, NY.
Address correspondence and reprint requests to Dr. John T. Kissel, Department of Neurology, Division of Neuromuscular Disease, The Ohio State University Medical Center, 1654 Upham Drive, Columbus, OH 43210.
Background/Objectives: — Animal and human studies suggest that ß2-adrenergic agonists exert anabolic effects on muscles, inducing and preventing atrophy after a variety of insults. Based on data from an open-label trial of albuterol in 15 patients with facioscapulohumeral dystrophy (FSHD), the authors conducted a randomized, double-blind, placebo-controlled trial of sustained-release albuterol in this disease.
Methods: — Ninety patients were randomized to three groups: placebo; 8.0 mg albuterol twice daily; or 16.0 mg albuterol twice daily. Patients were treated for 1 year with assessments at baseline and weeks 13, 26, and 52. The primary outcome was the 52-week change in global strength by maximum voluntary isometric contraction testing (MVICT). Secondary outcomes included changes at 52 weeks in strength by manual muscle testing (MMT), grip strength, functional testing, and muscle mass assessed by dual energy x-ray absorptiometry (DEXA).
Results: — Eighty-four patients completed the study. The mean changes in composite MVICT scores were not significantly different between the groups (mean ± SD: placebo 0.20 ± 0.91; low dose -0.04 ± 0.84; high dose 0.08 ± 0.98). Similarly, there were no differences in the mean MMT change (placebo 0.04 ± 0.16; low dose -0.03 ± 0.13; high dose 0.00 ± 0.15). Grip improved in both treatment groups compared to placebo (placebo -0.53 ± 4.13, low dose +1.90 ± 3.34 [p = 0.02], high dose +1.70 ± 4.13 [p = 0.03]). The high-dose group had a significant increase in lean mass by DEXA (+1.57 ± 1.71 kg) compared to placebo (0.25 ± 2.24; p = 0.007). Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness.
Conclusions: — Although albuterol did not improve global strength or function in patients with FSHD, it did increase muscle mass and improve some measures of strength.
This article has been cited by other articles:
|
|
 |
|
  J. G. Ryall, J. D. Schertzer, K. T. Murphy, A. M. Allen, and G. S. Lynch Chronic {beta}2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2587 - H2595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Skura, E. G. Fowler, G. T. Wetzel, M. Graves, and M. J. Spencer Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy Neurology, January 8, 2008; 70(2): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Swoboda, J. T. Kissel, T. O. Crawford, M. B. Bromberg, G. Acsadi, G. D'Anjou, K. J. Krosschell, S. P. Reyna, M. K. Schroth, C. B. Scott, et al. Perspectives on Clinical Trials in Spinal Muscular Atrophy J Child Neurol, August 1, 2007; 22(8): 957 - 966. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Elsheikh, E. Bollman, M. Peruggia, W. King, G. Galloway, and J. T. Kissel PILOT TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY Neurology, April 24, 2007; 68(17): 1428 - 1429. [Full Text] [PDF]
|
|
|
|
 |
|
 W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Caruso, J. Hamill, M. Yamauchi, D. Mercado, T. Cook, B. Higginson, S. O'Meara, J. Elias, and S. Siconolfi Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses J Appl Physiol, May 1, 2005; 98(5): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L. van der Kooi, O.J.M. Vogels, R.J.G.P. van Asseldonk, E. Lindeman, J.C.M. Hendriks, M. Wohlgemuth, S.M. van der Maarel, and G.W. Padberg Strength training and albuterol in facioscapulohumeral muscular dystrophy Neurology, August 24, 2004; 63(4): 702 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Fowler, M. C. Graves, G. T. Wetzel, and M. J. Spencer Pilot trial of albuterol in Duchenne and Becker muscular dystrophy Neurology, March 23, 2004; 62(6): 1006 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Desaphy, S. Pierno, A. De Luca, P. Didonna, and D. C. Camerino Different Ability of Clenbuterol and Salbutamol to Block Sodium Channels Predicts Their Therapeutic Use in Muscle Excitability Disorders Mol. Pharmacol., March 1, 2003; 63(3): 659 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, P. Gregorevic, D. R. Plant, M. N. Sillence, and G. S. Lynch beta 2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1386 - R1394. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
